Sangamo Therapeutics, Inc.SGMONASDAQ
Loading
Operating Expenses Over TimeContracting
Percentile Rank67
3Y CAGR-22.1%
5Y CAGR+16.2%
Studio
Year-over-Year Change

Expenses from normal business operations (SG&A, R&D, etc.)

3Y CAGR
-22.1%/yr
vs +16.8%/yr prior
5Y CAGR
+16.2%/yr
Recent deceleration
Acceleration
-38.9pp
Decelerating
Percentile
P67
Within normal range
vs 5Y Ago
2.1x
Strong expansion
Streak
2 yr
Consecutive declineContracting
PeriodValueYoY Change
TTM$141.90M-12.3%
2024$161.77M-64.1%
2023$450.24M+49.8%
2022$300.47M+2.2%
2021$294.04M+338.2%
2020$67.10M+8.8%
2019$61.69M-61.8%
2018$161.60M+73.9%
2017$92.93M+1.1%
2016$91.95M-